Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis

Multiple Sclerosis Journal

Volumn 18, Issue 6, 2012, Pages 799-806

  Simpson, Steve ^a   Taylor, Bruce ^a   Dwyer, Dominic E ^b   Taylor, Janette ^b   Blizzard, Leigh ^a   Ponsonby, Anne Louise ^c   Pittas, Fotini ^d   Dwyer, Terence ^c   Van Der Mei, Ingrid ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Epidemiology; Epstein Barr virus; human herpesvirus 6; multiple sclerosis

Indexed keywords

EPSTEIN BARR VIRUS ANTIBODY; HUMAN HERPESVIRUS 6 ANTIBODY; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY TITER; DISABILITY SEVERITY; DISEASE ASSOCIATION; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; HUMAN HERPESVIRUS 6; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDY; RELAPSE; REVIEW; SEX DIFFERENCE;

EID: 84861795775     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511428081     Document Type: Review

References (37)

1. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis. 2010 ; 29: 857-866
2. Lucas RM, Ponsonby AL, Dear K, et al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology. 2011 ; 77: 371-379
3. Moore FG, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand. 2002 ; 106: 63-83
4. Christensen T. Human herpesviruses in MS. Int MS J. 2007 ; 14: 41-47
5. Tejada-Simon MV, Zang YC, Hong J, Rivera VM, Zhang JZ. Cross-reactivity with myelin basic protein and human herpesvirus-6 in multiple sclerosis. Ann Neurol. 2003 ; 53: 189-197
6. Lunemann JD, Jelcic I, Roberts S, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-{gamma} and IL-2. J Exp Med. 2008 ; 205: 1763-1773
7. Cirone M, Cuomo L, Zompetta C, et al. Human herpesvirus 6 and multiple sclerosis: a study of T cell cross-reactivity to viral and myelin basic protein antigens. J Med Virol. 2002 ; 68: 268-272
8. Wandinger K, Jabs W, Siekhaus A, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology. 2000 ; 55: 178-184
9. Buljevac D, van Doornum GJ, Flach HZ, et al. Epstein-Barr virus and disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005 ; 76: 1377-1381
10. Berti R, Brennan MB, Soldan SS, et al. Increased detection of serum HHV-6 DNA sequences during multiple sclerosis (MS) exacerbations and correlation with parameters of MS disease progression. J Neurovirol. 2002 ; 8: 250-256
11. Alvarez-Lafuente R, De Las Heras V, Bartolome M, Picazo JJ, Arroyo R. Beta-interferon treatment reduces human herpesvirus-6 viral load in multiple sclerosis relapses but not in remission. Eur Neurol. 2004 ; 52: 87-91
12. Höllsberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, Haahr S. Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta Neurol Scand. 2005 ; 112: 395-402
13. Alvarez-Lafuente R, De Las Heras V, Bartolome M, Garcia-Montojo M, Arroyo R. Human herpesvirus 6 and multiple sclerosis: a one-year follow-up study. Brain Pathol. 2006 ; 16: 20-27
14. Garcia-Montojo M, De Las Heras V, Dominguez-Mozo M, et al. Human herpesvirus 6 and effectiveness of interferon beta 1b in multiple sclerosis patients. Eur J Neurol. 2011 ; 18: 1027-1035
15. Goldberg SH, Albright AV, Lisak RP, Gonzalez-Scarano F. Polymerase chain reaction analysis of human herpesvirus-6 sequences in the sera and cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol. 1999 ; 5: 134-139
16. Behzad-Behbahani A, Mikaeili MH, Entezam M, et al. Human herpesvirus-6 viral load and antibody titer in serum samples of patients with multiple sclerosis. J Microbiol Immunol Infect. 2011 ; 44: 247-251
17. Farrell RA, Antony D, Wall GR, et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009 ; 73: 32-38
18. Castellazzi M, Tamborino C, Cani A, et al. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis. Mult Scler. 2010 ; 16: 883-887
19. Ingram G, Bugert JJ, Loveless S, Robertson NP. Anti-EBNA-1 IgG is not a reliable marker of multiple sclerosis clinical disease activity. Eur J Neurol. 2010 ; 17: 1386-1389
20. Villoslada P, Juste C, Tintore M, et al. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology. 2003 ; 60: 1944-1948
21. Soldan SS, Berti R, Salem N, et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med. 1997 ; 3: 1394-1397
22. Pittas F, Ponsonby AL, van der Mei IA, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol. 2009 ; 256: 577-585
23. Simpson SL, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in MS. Ann Neurol. 2010 ; 68: 193-203
24. Tuke PW, Hawke S, Griffiths PD, Clark DA. Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains. Mult Scler. 2004 ; 10: 355-359
25. Challoner PB, Smith KT, Parker JD, et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. Proc Natl Acad Sci U S A. 1995 ; 92: 7440-7444
26. Ahlqvist J, Fotheringham J, Akhyani N, Yao K, Fogdell-Hahn A, Jacobson S. Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes. J Neurovirol. 2005 ; 11: 384-394
27. Donati D, Martinelli E, Cassiani-Ingoni R, et al. Variant-specific tropism of human herpesvirus 6 in human astrocytes. J Virol. 2005 ; 79: 9439-9448
28. Fotheringham J, Williams EL, Akhyani N, Jacobson S. Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes. J Neuroimmune Pharmacol. 2008 ; 3: 105-116
29. Yao K, Graham J, Akahata Y, Oh U, Jacobson S. Mechanism of neuroinflammation: enhanced cytotoxicity and IL-17 production via CD46 binding. J Neuroimmune Pharmacol. 2010 ; 5: 469-478
30. Luttichau HR, Clark-Lewis I, Jensen PO, Moser C, Gerstoft J, Schwartz TW. A highly selective CCR2 chemokine agonist encoded by human herpesvirus 6. J Biol Chem. 2003 ; 278: 10928-10933
31. Christensen T. Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol. 2005 ; 15: 179-211
32. Blond JL, Beseme F, Duret L, et al. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol. 1999 ; 73: 1175-1185
33. Perron H, Bernard C, Bertrand JB, et al. Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis. J Neurol Sci. 2009 ; 286: 65-72
34. Perron H, Lazarini F, Ruprecht K, et al. Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol. 2005 ; 11: 23-33
35. Derfuss T, Hohlfeld R, Meinl E. Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell response. J Neurol. 2005 ; 252: 968-971
36. Braun DK, Dominguez G, Pellett PE. Human herpesvirus 6. Clin Microbiol Rev. 1997 ; 10: 521-567
37. Iuliano R, Trovato R, Lico S, et al. Human herpesvirus-6 reactivation in a longitudinal study of two HIV-1 infected patients. J Med Virol. 1997 ; 51: 259-264